Sean et al., Wirchows Archiv describe the validation of eight commercial antibodies raised against ROR2. This commonly used antibody was one of three antibodies tested by western blots on colorectal cancer cell lines (used 1:1000). The antibody detected a protein at approximately 97 kDa in both cells with high expression levels and in cells predicted to lack expression. This was slightly lower than the predicted 105 kDa size for ROR2. The observed expression was higher in the cells predicted to have high expression levels.
When immunostaining cells overexpressing ROR2, the antibody was able to detect the expression when used at 1:500. Similarly, the antibody also worked for staining tissue samples from patients suffering from colorectal cancer (1:500). See full description in the article.
On April 23, 2018 Caroline Ford wrote:
Sean et al., Wirchows Archiv describe the validation of eight commercial antibodies raised against ROR2. This commonly used antibody was one of three antibodies tested by western blots on colorectal cancer cell lines (used 1:1000). The antibody detected a protein at approximately 97 kDa in both cells with high expression levels and in cells predicted to lack expression. This was slightly lower than the predicted 105 kDa size for ROR2. The observed expression was higher in the cells predicted to have high expression levels.
When immunostaining cells overexpressing ROR2, the antibody was able to detect the expression when used at 1:500. Similarly, the antibody also worked for staining tissue samples from patients suffering from colorectal cancer (1:500). See full description in the article.